CVRx Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $15
CVRx Analyst Ratings
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Lake Street Remains a Buy on CVRx (CVRX)
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)
Lake Street Keeps Their Buy Rating on CVRx (CVRX)
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $26
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Raises Target Price to $15
Piper Sandler Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $13
CVRx Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for CVRx (CVRX)
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12